Heartflow (HTFL) FDA Approvals $32.24 +1.04 (+3.33%) Closing price 04:00 PM EasternExtended Trading$31.92 -0.32 (-0.99%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Heartflow's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Heartflow (HTFL). Over the past two years, Heartflow has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as FISH&CHIPS. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. FISH&CHIPS FDA Regulatory Events FISH&CHIPS is a drug developed by Heartflow for the following indication: Heartflow Plaque Analysis with Heartflow Plaque Staging. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Presentation - November 9,2025Presentation Drug: FISH&CHIPSAnnounced Date: November 9, 2025Indication: Heartflow Plaque Analysis with Heartflow Plaque StagingAnnouncementHeartflow, Inc announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association (AHA) Scientific Sessions 2025.AI SummaryHeartflow, Inc. announced late-breaking data from the FISH&CHIPS Study presented at the AHA Scientific Sessions 2025. A retrospective analysis of nearly 8,000 symptomatic patients validated Heartflow Plaque Staging based on total plaque volume (TPV) — the largest validation to date. Patients in the highest TPV stage had more than a fivefold higher risk of major cardiovascular events than those in the lowest stage (hazard ratio 5.10, p<0.0001). Higher plaque stages were independently linked to increased rates of cardiovascular death and myocardial infarction over a median 3.3 years. These associations held after adjusting for coronary stenosis, FFRCT and standard risk factors. Investigators said TPV-based staging can help predict who is most at risk and support personalized treatment to prevent heart attacks and death. Heartflow says the data add to growing evidence that AI-powered plaque measurement can change clinical decision making and guide more targeted care.Read Announcement Heartflow FDA Events - Frequently Asked Questions Has Heartflow received FDA approval? As of now, Heartflow (HTFL) has not received any FDA approvals for its therapy in the last two years. What drugs has Heartflow submitted to the FDA? In the past two years, Heartflow (HTFL) has reported FDA regulatory activity for FISH&CHIPS. What is the most recent FDA event for Heartflow? The most recent FDA-related event for Heartflow occurred on November 9, 2025, involving FISH&CHIPS. The update was categorized as "Presentation," with the company reporting: "Heartflow, Inc announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association (AHA) Scientific Sessions 2025." What conditions do Heartflow's current drugs treat? Currently, Heartflow has one therapy (FISH&CHIPS) targeting the following condition: Heartflow Plaque Analysis with Heartflow Plaque Staging. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Agenus FDA EventsApyx Medical FDA EventsAtossa Genetics FDA EventsBiogen FDA EventsBioLineRx FDA EventsCAMP4 Therapeutics FDA EventsCelcuity FDA EventsClimb Bio FDA EventsCorvus Pharmaceuticals FDA EventsEditas Medicine FDA EventsEyepoint Pharmaceuticals FDA EventsGenprex FDA EventsGT Biopharma FDA EventsMiNK Therapeutics FDA EventsINmune Bio FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Celcuity FDA Events Veracyte FDA Events Definium Therapeutics FDA Events Viridian Therapeutics FDA Events CareDx FDA Events Personalis FDA Events Castle Biosciences FDA Events Fulgent Genetics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:HTFL last updated on 11/10/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredMillionaire warns: Move your money before May 15Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...Brownstone Research | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heartflow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heartflow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presentation - November 9,2025Presentation Drug: FISH&CHIPSAnnounced Date: November 9, 2025Indication: Heartflow Plaque Analysis with Heartflow Plaque StagingAnnouncementHeartflow, Inc announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association (AHA) Scientific Sessions 2025.AI SummaryHeartflow, Inc. announced late-breaking data from the FISH&CHIPS Study presented at the AHA Scientific Sessions 2025. A retrospective analysis of nearly 8,000 symptomatic patients validated Heartflow Plaque Staging based on total plaque volume (TPV) — the largest validation to date. Patients in the highest TPV stage had more than a fivefold higher risk of major cardiovascular events than those in the lowest stage (hazard ratio 5.10, p<0.0001). Higher plaque stages were independently linked to increased rates of cardiovascular death and myocardial infarction over a median 3.3 years. These associations held after adjusting for coronary stenosis, FFRCT and standard risk factors. Investigators said TPV-based staging can help predict who is most at risk and support personalized treatment to prevent heart attacks and death. Heartflow says the data add to growing evidence that AI-powered plaque measurement can change clinical decision making and guide more targeted care.Read Announcement
